245 related articles for article (PubMed ID: 20354680)
1. Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.
Walentiny DM; Vann RE; Warner JA; King LS; Seltzman HH; Navarro HA; Twine CE; Thomas BF; Gilliam AF; Gilmour BP; Carroll FI; Wiley JL
Psychopharmacology (Berl); 2010 Jun; 210(2):275-84. PubMed ID: 20354680
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors.
Capasso R; Borrelli F; Cascio MG; Aviello G; Huben K; Zjawiony JK; Marini P; Romano B; Di Marzo V; Capasso F; Izzo AA
Br J Pharmacol; 2008 Nov; 155(5):681-9. PubMed ID: 18622408
[TBL] [Abstract][Full Text] [Related]
3. Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo.
Aviello G; Borrelli F; Guida F; Romano B; Lewellyn K; De Chiaro M; Luongo L; Zjawiony JK; Maione S; Izzo AA; Capasso R
J Mol Med (Berl); 2011 Sep; 89(9):891-902. PubMed ID: 21499737
[TBL] [Abstract][Full Text] [Related]
4. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
[TBL] [Abstract][Full Text] [Related]
5. Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents.
Braida D; Capurro V; Zani A; Rubino T; Viganò D; Parolaro D; Sala M
Br J Pharmacol; 2009 Jul; 157(5):844-53. PubMed ID: 19422370
[TBL] [Abstract][Full Text] [Related]
6. FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.
Falenski KW; Thorpe AJ; Schlosburg JE; Cravatt BF; Abdullah RA; Smith TH; Selley DE; Lichtman AH; Sim-Selley LJ
Neuropsychopharmacology; 2010 Jul; 35(8):1775-87. PubMed ID: 20357755
[TBL] [Abstract][Full Text] [Related]
7. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.
Braida D; Limonta V; Pegorini S; Zani A; Guerini-Rocco C; Gori E; Sala M
Psychopharmacology (Berl); 2007 Mar; 190(4):441-8. PubMed ID: 17219220
[TBL] [Abstract][Full Text] [Related]
8. The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.
Butelman ER; Rus S; Prisinzano TE; Kreek MJ
Psychopharmacology (Berl); 2010 Jun; 210(2):253-62. PubMed ID: 20084367
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
[TBL] [Abstract][Full Text] [Related]
10. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse.
Fantegrossi WE; Kugle KM; Valdes LJ; Koreeda M; Woods JH
Behav Pharmacol; 2005 Dec; 16(8):627-33. PubMed ID: 16286814
[TBL] [Abstract][Full Text] [Related]
11. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward.
Braida D; Limonta V; Capurro V; Fadda P; Rubino T; Mascia P; Zani A; Gori E; Fratta W; Parolaro D; Sala M
Biol Psychiatry; 2008 Feb; 63(3):286-92. PubMed ID: 17920565
[TBL] [Abstract][Full Text] [Related]
12. The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.
Butelman ER; Harris TJ; Kreek MJ
Psychopharmacology (Berl); 2004 Mar; 172(2):220-4. PubMed ID: 14586540
[TBL] [Abstract][Full Text] [Related]
13. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
[TBL] [Abstract][Full Text] [Related]
14. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.
Wiley JL; Breivogel CS; Mahadevan A; Pertwee RG; Cascio MG; Bolognini D; Huffman JW; Walentiny DM; Vann RE; Razdan RK; Martin BR
Eur J Pharmacol; 2011 Jan; 651(1-3):96-105. PubMed ID: 21114999
[TBL] [Abstract][Full Text] [Related]
15. The great divide: Separation between in vitro and in vivo effects of PSNCBAM-based CB
Gamage TF; Farquhar CE; Lefever TW; Thomas BF; Nguyen T; Zhang Y; Wiley JL
Neuropharmacology; 2017 Oct; 125():365-375. PubMed ID: 28803965
[TBL] [Abstract][Full Text] [Related]
16. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
Chavkin C; Sud S; Jin W; Stewart J; Zjawiony JK; Siebert DJ; Toth BA; Hufeisen SJ; Roth BL
J Pharmacol Exp Ther; 2004 Mar; 308(3):1197-203. PubMed ID: 14718611
[TBL] [Abstract][Full Text] [Related]
17. A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.
Cruz A; Domingos S; Gallardo E; Martinho A
Phytochemistry; 2017 May; 137():9-14. PubMed ID: 28190678
[TBL] [Abstract][Full Text] [Related]
18. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.
Sim-Selley LJ; Martin BR
J Pharmacol Exp Ther; 2002 Oct; 303(1):36-44. PubMed ID: 12235230
[TBL] [Abstract][Full Text] [Related]
19. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice.
Capasso R; Borrelli F; Zjawiony J; Kutrzeba L; Aviello G; Sarnelli G; Capasso F; Izzo AA
Neurogastroenterol Motil; 2008 Feb; 20(2):142-8. PubMed ID: 17931335
[TBL] [Abstract][Full Text] [Related]
20. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
